Nemod and IDM Announce the Signature of a Joint Research Agreement.Business Editors PARIS--(BUSINESS WIRE)--October 24, 2002 Immuno-Designed Molecules, S.A. (IDM (1) See identity management. (2) (Integrated Device Manufacturer) A company that performs every step of the chip-making process, including design, manufacture, test and packaging. Examples of IDMs are Intel, AMD, Motorola, IBM, TI and Lucent. ) and Nemod Immunotherapies AG, a German biotechnology company based in Berlin-Buch, have entered a joint research project to develop new immunotherapy products in cancer treatment. The research project aims at evaluating the potential synergy between some Nemod's antibodies and IDM's MAK Mak Falstaffian figure; categorically maintains his innocence. [Br. Lit.: The Second Shepherds’ Play] See : Deceit Mak sheep stealer succeeds by waiting till the shepherds fall asleep. [Br. Lit. (R) (Monocyte-derived Activated Killer) cells to target and destroy tumor cells. If this evaluation is successful, IDM will be granted an exclusive license with Nemod in the field of ex vivo therapy ex vivo therapy Molecular medicine A therapy in which cells or genes are modified out of the body and reintroduced into a person with a genetic disease. See Gene therapy. , allowing IDM to further develop and commercialize several new products to fight cancers such as colon, gastric, breast, prostate and ovarian cancer ovarian cancer Malignant tumour of the ovaries. Risk factors include early age of first menstruation (before age 12), late onset of menopause (after age 52), absence of pregnancy, presence of specific genetic mutations, use of fertility drugs, and personal history of breast . One of Nemod's areas of expertise is in glycobiology applied to therapeutic antibodies. Nemod has developed antibodies recognizing unique glycosylation patterns on three pan-carcinomic epitopes or antigens: MUC MUC Mount Union College (Ohio) MUC Multi User Chat MUC Message Understanding Conference MUC Montreal Urban Community MUC Malaspina University College (Canada) 1, TF-Thomson Friedenreich and Lewis Y. TF is an antigen expressed only on tumors, primarily gastric and colorectal tumors, while MUC1 is over expressed in breast and ovarian cancer. Lewis Y are blood group antigens and are tumor associated antigens found in breast, prostate, hepatocarcinoma and Non Small Cell Lung cancers. "Acces to Nemod antibody technology opens up new avenues in the development of our MAK(R) based products to destroy cancer cells. This strongly enhances the range of IDM's Cell Drug portfolio under clinical development," said Jean-Loup Romet-Lemonne, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of IDM. IDM - The Immunogenics Company(R) IDM is a leading biopharmaceutical company developing a new family of immunotherapy products called Cell Drugs(TM) to fight cancer and other life-threatening diseases. IDM applies its proprietary technologies to selectively isolate, engineer, expand and activate specific cell populations which are involved in therapeutic vaccination. The Company's products are designed to boost the immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. , destroy residual tumor cells, and immunize im·mu·nize v. 1. To render immune. 2. To produce immunity in, as by inoculation. im patients to prevent tumor recurrence. IDM's most advanced product is in Phase III for the treatment of ovarian cancer. For more information, please visit IDM's Web site, http://www.idm-biotech.com
IDM Paris Headquarters 172 rue de Charonne
75011 Paris FRANCE
tel +33 (0) 1 40 09 04 11
fax +33 (0) 1 40 09 04 25
e-mail idm@idm-biotech.com
|
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion